PPARA and fatty liver disease: In a previously identified study, it was found that the effect of 4-(benzo[d]thiazol-2-yl)benzene-1,3-diol (MHY553), a novel PPARα agonist, alleviated hepatic steatosis through an increase of fatty acid oxidation and a decrease in inflammation in aged rats [13].